Cargando…

Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)

SIMPLE SUMMARY: Neuroendocrine tumors grade 3 (NET G3) are a newly defined subgroup of neuroendocrine neoplasms. They do not respond well to platinum + etoposide-based chemotherapy. The alternative suggested options have not been analyzed in untreated NET G3 patients so far, therefore the optimal tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apostolidis, Leonidas, Dal Buono, Arianna, Merola, Elettra, Jann, Henning, Jäger, Dirk, Wiedenmann, Bertram, Winkler, Eva Caroline, Pavel, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073753/ https://www.ncbi.nlm.nih.gov/pubmed/33923759 http://dx.doi.org/10.3390/cancers13081936

Ejemplares similares

Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms
por: Apostolidis, Leonidas, et al.
Publicado: (2021)

Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma
por: Apostolidis, Leonidas, et al.
Publicado: (2016)

Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial
por: Krug, Sebastian, et al.
Publicado: (2021)

Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
por: Detjen, Katharina M., et al.
Publicado: (2021)

Grade 3 Neuroendocrine Tumor (G3NET): An Unusual Tumor With A Histochemical Surprise
por: Singhal, Sachi, et al.
Publicado: (2021)

PD-L1 – inhibitors in neuroendocrine neoplasia: Results from a real-life study
por: Özdirik, Burcin, et al.
Publicado: (2021)

Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
por: Zappi, Arianna, et al.
Publicado: (2023)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review
por: Özdirik, Burcin, et al.
Publicado: (2020)

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor
por: Williamson, Laura M., et al.
Publicado: (2019)

Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report
por: Ito, Misato, et al.
Publicado: (2020)

Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors
por: Hashmi, Atif A, et al.
Publicado: (2021)

Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms
por: Kidess, Evelyn, et al.
Publicado: (2023)

Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
por: Pellat, Anna, et al.
Publicado: (2020)

Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
por: Pellat, Anna, et al.
Publicado: (2021)

Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice
por: Luecke, Simone, et al.
Publicado: (2022)

The impact of COVID‐19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients
por: Cives, Mauro, et al.
Publicado: (2022)

A Well-Differentiated Grade-3 Neuroendocrine Tumor in the Ascending Colon: A Case Report
por: AlSaffar, Ali, et al.
Publicado: (2022)

A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3)
por: Laffi, Alice, et al.
Publicado: (2021)

Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease
por: Miki, Masami, et al.
Publicado: (2018)

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
por: Apostolidis, Leonidas, et al.
Publicado: (2019)

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study
por: Boutin, Mélina, et al.
Publicado: (2022)

Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment
por: Lamarca, Angela, et al.
Publicado: (2021)

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
por: Diamantopoulos, Leonidas N., et al.
Publicado: (2023)

Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis
por: Merola, Elettra, et al.
Publicado: (2017)

Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors
por: Geisler, Lukas, et al.
Publicado: (2022)

Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors
por: Reinhard, Lisa, et al.
Publicado: (2023)

Gastric neuroendocrine neoplasias: manifestations and comparative outcomes
por: Felder, S, et al.
Publicado: (2019)

Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs
por: Singh, Simron, et al.
Publicado: (2016)

Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification
por: Xu, Jun-Xi, et al.
Publicado: (2021)

Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality
por: Fazio, Nicola, et al.
Publicado: (2017)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia
por: Abdelmalak, Rebecca, et al.
Publicado: (2021)

Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors
por: Kim, Min Jeong, et al.
Publicado: (2018)

Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case
por: Manneh, Ray, et al.
Publicado: (2016)

Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs
por: Laffi, Alice, et al.
Publicado: (2023)

Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals
por: Leyden, Simone, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m6p67lag5ohu473v14b259qojl